BioSpace News Archive

CareDx, Inc. announced that its strategic partner, Cibiltech, a French MedTech company that develops artificial intelligence-based products for predictive medicine, has initiated the CIBIL clinical trial to evaluate the performance of iBox artificial intelligence as a prognostic measure of organ survival in kidney transplant patients.

HUTCHMED Limited reports its audited financial results for the year ended December 31, 2021 and provides updates on key clinical and commercial developments since the start of 2022.

Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record revenue of $48.7 million, net income of $32.7 million, or $0.19 per diluted earnings per share, and adjusted net income of $4.1 million, or $0.02 per adjusted diluted earnings per share, which excludes the gain on the sale of OTREXUP®.

Lantern Pharma announced today that it will host a conference call on Thursday, March 10th, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time.

BioLineRx Ltd. today announced additional positive results from a follow-on pharmacoeconomic study that was performed based on data from the Company’s successful Phase 3 GENESIS trial.

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it will present at the 34th Annual ROTH Conference being held both virtually and in-person in Dana Point, California on March 13-15, 2022.

PREDICT Registry Meets Phase One Accrual Goal of 2,500 Patients; Largest Ongoing Prospective Ductal Carcinoma in Situ Study in the World.

Unicycive Therapeutics, Inc. today announced that Shalabh Gupta , M.D., Chief Executive Officer of Unicycive, will participate at two upcoming investor conferences in March.

Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced that company management will participate in the 32nd Annual Oppenheimer Healthcare Conference, taking place virtually March 15-17, 2022.

Dyne Therapeutics, Inc. today announced the appointment of Carlo Incerti, M.D., to its Board of Directors.